2018
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
Garces A, Ang J, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. European Journal Of Cancer 2018, 104: 32-38. PMID: 30316017, PMCID: PMC6259582, DOI: 10.1016/j.ejca.2018.08.019.Peer-Reviewed Original ResearchConceptsPhase I clinical trialElectrolyte abnormalitiesBaseline hypoalbuminaemiaOverall survivalClinical significanceDose-limiting toxicity windowPrognostic factors of OSOncology phase I trialsInferior median OSFactors of OSPhase I patientsPhase I trialRetrospective chart reviewSerum albumin levelAssociated with hypomagnesaemiaRoyal Marsden HospitalCox regression analysisPhase I populationDrug Development UnitMedian OSPrognostic factorsPrognostic significanceI patientsI trialAlbumin levels
2017
398P Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital
Garces A, Ang J, Ameratunga M, Chenard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U. 398P Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital. Annals Of Oncology 2017, 28: v132-v133. DOI: 10.1093/annonc/mdx367.031.Peer-Reviewed Original Research